🌟 Celebrating 10 Years of the IPF Summit
Over the past ten years, the IPF Summit has earned its reputation as the industry’s most comprehensive and respected meeting dedicated exclusively to IPF and progressive fibrotic lung disease. Each year, we bring together:
- World‑class IPF researchers
- Leading biopharma and biotech drug developers
- Clinical trial innovators
- Translational and biomarker experts
- Regulatory and safety specialists
This year’s faculty continues that tradition, a powerhouse lineup of experts ready to share new data, challenge assumptions, and accelerate progress.
On Event Context:
On Event Experience:
On Networking:
Key top-level experts sharing their experiences not only of success but also of failure, and constructive and open discussions throughout the entire meeting made it worth the 9 hours flight to Boston.
Senior Researcher, GAT Therapeutics
Attending the IPF Summit 2025 in Boston for the first time was an exceptional experience. The summit brought together top-tier speakers and a thoughtfully designed program that balanced clinical, preclinical, and combined tracks, fostering a comprehensive view of the field. The networking sessions stood out, providing meaningful opportunities to engage with peers, exchange ideas, and gain fresh perspectives. This summit was not just an event—it was an inspiring platform for growth, collaboration, and learning, and I am genuinely grateful to have been part of it.
Director - In Vivo Pharmacology/immunology, Tectonic Therapeutic
Opportunity to network and diverse topics covering all stages of drug development.
Head of Clinical Development Pulmonology & Rheumatology, Boehringer Ingelheim
I would recommend this excellent IPF summit to anyone interested to learn fast or get updates from the best IPF experts! I always rely on this conference to get up to date and discuss the most relevant IPF science and drug development!
Medical Director, Respiratory, Novartis AG
All the conference leaders and presenters were engaging and welcomed questions and follow-up dialogue. The science and clinical information that was shared was dynamic and insightful, ranging from early-stage drug development through late-stage clinical.
Co-Founder, Artasome Therapeutics
Great presentations; able to interact with other colleagues.
Senior Vice President, Global Clinical Development (Non-Oncology), Insilico Medicine
An excellent and high-quality conference covering all key concepts within IPF drug development.
Oslo University Hospital Research
The set up of the meeting is great. The size is manageable and I was able to meet a lot of people, and the talks were high quality.
Senior VP, Clinical Operations, Endeavor Biomedicines
Very good group, engaging and enthusiastic speakers.
Director - Business Development & Early Pipeline commercial evaluation, Insmed
The quality of speakers and attendees really stood out. This conference clearly attracts a core of the IPF community, and it makes a big difference.
Senior Associate, Sant Ventures
Everyone there has the same vision and purpose.
Senior Director, Fortrea Inc.
I really enjoyed the intimate setting without too many vendors. The small subgroups and panels made it easy for fluid conversation from the whole group.
Business Development Manager, Insmed
The diversity of topics across innovative biology and clinical development in a small setting makes this a unique conference.
Head of Discovery Pharmacology, Altos Labs
Very good group, engaging and enthusiastic speakers.
Director - Business Development & Early Pipeline commercial evaluation, Insmed
Top notch speakers, great networking, plenty of free time to chat.
Chair, PROLIFIC, Pulmonary Fibrosis Foundation
Learning about the trend at the front via high level leaders of pharma. Networking with active researchers/developers directly.
Scientist, Boston University
I really enjoyed the intimate setting without too many vendors. The small subgroups and panels made it easy for fluid conversation from the whole group.
Business Development Manager, Insmed
Connecting with colleagues - other IPF companies, vendors, and experts in IPF - was invaluable. We all had honest conversations about our challenges, and it felt like people wanted to help each other.
Vice President - Medical Affairs, PureTech Health
I was able to learn about the current trends in IPF drug development.
Scientist, Dong-A ST
I truly appreciate the scale of the summit and the diversity of attendees, ranging from small biotech and large pharma to clinicians and academics. This diversity creates a valuable opportunity for cross-disciplinary learning, identification of gaps, and alignment on the trajectory of IPS/ILD research. Additionally, it fosters potential collaborations among experts from various fields.
Inflammation Drug Discovery Research Scientist, Takeda Pharmaceutical
The quality of speakers and attendees really stood out. This conference clearly attracts a core of the IPF community, and it makes a big difference.
Senior Associate, Sant Ventures
This conference given the opportunity to understand the IPF clinical studies, the underlying research topics and networking.
Senior Scientist, Ionis Pharmaceuticals, Inc.
I thought the quality of the actual content and ability to engage the audience frequently was stellar.
Medical Director, Vertex Pharmaceuticals
Attending the IPF Summit 2025 in Boston for the first time was an exceptional experience. The summit brought together top-tier speakers and a thoughtfully designed program that balanced clinical, preclinical, and combined tracks, fostering a comprehensive view of the field. The networking sessions stood out, providing meaningful opportunities to engage with peers, exchange ideas, and gain fresh perspectives. This summit was not just an event—it was an inspiring platform for growth, collaboration, and learning, and I am genuinely grateful to have been part of it.
Director - In Vivo Pharmacology/immunology, Tectonic Therapeutic
I enjoyed the discussions around endpoints and the reasons why previous IPF programs have failed.
Executive Director & Lead - Respiratory Medicine Franchise Area, Worldwide Clinical Trials
The attendees are of high quality and experienced IPF researchers. The conference atmosphere was very friendly and encouraged everyone to participate and exchange the information.
Chief Executive Officer, Ark Biosciences
Meeting leaders in the field and hearing the latest developments. presentations from startups and Biotech were very useful.
Early Drug Discovery & Development Consultant, Tribune Therapeutics
The overall agenda of topics and discussions were great, but in particular I was glad to participate in the preconference workshops. I felt they were valuable for both those new to the filed or experienced in IPF research.
Principal Scientist – Research, AbbVie
Always a pleasure to learn the latest about IPF from leading experts in the field of IPF. I especially enjoy the round table and panel discussions; it is a good opportunity for people trying to better understand the field to engage with senior people in the field.
Instructor, University of Massachusetts Medical School
A small event where many people were able to share in an open conversation rather than just listen to presentations.
Head of Discovery Pharmacology, Altos Labs
I thought the quality of the actual content and ability to engage the audience frequently was stellar.
Medical Director, Vertex Pharmaceuticals
Great overview of IPF research from leaders in the field.
Professor, Boston University
Meeting has a unique mix of pharma and academic leaders combined with plenty of opportunities for networking- fantastic meeting!
Global Project, Respiratory Immunology Research & Development Leader, AstraZeneca
Great content delivered by great speakers. I did enjoy the clinical focus during the first day and less of it during the second day.
Vice President - Clinical Development Portfolio, Calliditas Therapeutics AB
The overall design of the meeting being smaller, everything felt like a discussion rather than the traditional talk/Q&A format at larger meetings. This was my first IPF Summit and HW event, and I thought it was well curated, and the facilitators for each session did a great job. The networking session during the morning of the first conference day was also a good experience compared with others I've had. Even though meeting attendees were potentially competitors in drug development, it felt collaborative.
Senior Scientist – Clinical, Cumberland Pharmaceuticals
I came to this conference to learn about the therapeutic landscape of IPF. This conference enabled me to hear about cutting edge translational research all the way through late-stage clinical trial design, as well as current-day thoughts and perspectives.
Scientific Director, GlaxoSmithKline
The networking was very valuable, and I learned a lot about the field. The scientific content of the talks was well balanced.
International Assignee, Daiichi Sankyo
Leaders in the IPF field were speakers. Speakers were very knowledgeable and helpful with questions. Great food and opportunity to network.
Associate Director, Biology, Enanta Pharmaceutical